How to Profit from America’s Deadliest Epidemic

Capitalism, not the government, will solve the opioid epidemic. Jeff Siegel looks at the latest government attempt to find a scapegoat and the companies that will really be pivotal in ending this epidemic... and making you money in the process. You are receiving this email because you subscribed to Energy and Capital. [Click here]( to manage your e-mail preferences. [Energy and Capital logo] How to Profit from America’s Deadliest Epidemic [Jeff Siegel Photo] By [Jeff Siegel]( Written Nov. 23, 2018 We’re a nation of blamers. Whenever we’re confronted with a problem, the first response is to find the “guilty party.” Who’s going to take the fall? Who’s going to be thrown under the bus? Who’s going to be placed in the modern-day stockades of social media criticism while armies of vulture ambulance chasers try to steal the wallets of roadkill pawns? In the latest move to end America’s opioid epidemic, the state of Florida is suing Walgreens and CVS, claiming that the two drugstore chains are partly to blame for the nation’s opioid crisis by “overselling painkillers and not taking precautions to stop illegal sales.” Walgreens and CVS are now part of a group of pharma companies and opioid distributors that are being targeted by the Sunshine State for essentially serving as a catalyst for the opioid epidemic. While there’s no doubt that there’s plenty of blame to go around, including the pharmaceutical companies and some of the less-ethical pharmacies and doctors, Florida’s lawsuit is not going to end the opioid problem we’re facing today. Lawsuits and opportunistic district attorneys cannot help folks end their addictions to opioids, nor can they keep folks from getting their hands on this stuff. And while I shed no tears for the pharmaceutical companies that have aggressively pushed doctors to prescribe these dangerous drugs, even when they weren’t necessary, the only thing that’s really going to make a dent in this very real crisis is capitalism. "3 Stocks to Cure America's Drug Crisis" They trade for $1, $4.60, and $25. Sales for these lifesaving drugs have skyrocketed. It's gone from $5 million only a few years ago to $29 million today. All three companies address the three most important and difficult challenges of this drug epidemic: - Prevention. - An overdose antidote. - A safe, nonaddictive pain reliever to replace opioids altogether. You can expect to make two times, three times, and even four times your money on these companies. Get in on this now by [clicking here](! This Is Personal I don’t mean to sound brash, but the bottom line is that if we wait for the government to fix this problem, we’ll be waiting a very long time, and a lot more folks will die. Fortunately, the free market has spawned a number of new solutions to the opioid epidemic that has been responsible for the deaths of more than 200,000 people. These solutions are being provided by companies that have developed medications that can bring folks back from overdoses. These are companies that have developed new treatments that can eliminate opioid addictions altogether. These are companies that have developed new painkillers that can work as legitimate replacements for some opioid medications, without the threat of addiction. I realize I may sound a bit over the top regarding this issue. But for me, it’s personal. Crisis = Opportunity Yesterday afternoon, as we sat around inhaling turkey, mashed potatoes, and cranberry sauce, it was hard to not think about some of my friends who have died over the past two years from opioid overdoes. That’s right, I said friends. As in more than one. Since 2017, I’ve had to say goodbye to three friends who all died of opioid overdoses. All three got addicted to these things pretty quickly, and all three overdosed because they couldn’t beat their addictions. These are people who had families. They had friends, cousins, brothers, and sisters. And this year, they weren’t sitting around the dinner table for Thanksgiving. They weren’t sharing the things they were thankful for. They weren’t talking about the “good old days” or sitting around the television watching the football game. Secret Army Research Lab Makes World-Changing Energy Breakthrough What was once little more than a laboratory experiment is quickly becoming the cheapest, cleanest, and most efficient alternative energy source. It's being adopted by the largest corporations on the planet. Apple, Google, and Amazon have all invested billions of dollars in this energy source. But there's one tiny company at the center of it all that could show investors 15 times their investments! [Click here to find out more about it!]( This, dear reader, is why earlier this year, I started investing in a few companies that are bringing very real solutions to the nation’s opioid epidemic. And while I’m already up double digits on these stocks, the real benefit here is knowing that I’m making money while helping to end the opioid epidemic. I’m not going to lie. It definitely takes some of the sting out of this crisis for me. But I’m not here to talk about my feelings. I’m here to do what I always do... Find an opportunity for you to make a ton of money. And no matter how you slice it, the opioid crisis has resulted in an opportunity for us to profit from all the things that are going to help end this tragedy. I’ve already identified three specific stocks that are helping us end the opioid epidemic. And you can [learn more about those stocks here](. You can also check out [this video](, which details all the different ways [you can profit from the solution to the opioid crisis](. Here’s the deal... There are few things more honorable than helping to end this plague that continues to steal our loved ones. And there are few things more satisfying than making money while helping to make the world a better place. If there’s one thing I can definitely be thankful for on the day after Thanksgiving, it’s that we live in a world in which we can utilize the free market to end one of the deadliest epidemics to ever strike the U.S. And we can profit while doing it. There’s just nothing better. [Click here now to join me.]( To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's [page](. --------------------------------------------------------------- [IN CASE YOU MISSED IT]( Lives Will Be Changed Forever Sometimes a document in the right hands at the right time can change the trajectory of your life. And that’s exactly what happened to this man when he stumbled upon one of the most valuable pieces of paper in existence at a family barbecue. That piece of paper was Apple’s prospectus. And when Apple started selling its shares to the public, this man and 299 other early investors literally became millionaires overnight. Getting in on an IPO makes for the most dramatic and profitable investments, which is why Jason Stutman crafted his IPO selection system — a system he’s just now opening to investors. It’s a system that manages to cut risk and increase respective returns by as much as 104%. If you want to feel as content as those 300 investors who got in at the ground floor of Apple, [click here]( to let Jason Stutman show you the beauty of his cutting-edge stock selection system. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [NG Trade Takes Hedge Fund to the Bone Yard]( [New York's Opioid Tax]( [Hydrogen Fuel Cell Technology Is Just Now Taking Off]( [Medical Cannabis Stocks Are Ripe for the Picking]( [The $25 Billion Secret Behind "Project Portal"]( Related Articles [Time to Buy U.S. Pot Stocks]( [Trump Can't Solve the Opioid Crisis. Only the Private Sector Can.]( [Medical Cannabis Stocks Are Ripe for the Picking]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2018, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.